Moderna for gene therapy: Like Moderna uses its mRNA platform to develop vaccines and therapies, Regenxbio uses its proprietary NAV technology platform to deliver genes for treating various diseases.

CRISPR Therapeutics, but for gene delivery: Similar to how CRISPR Therapeutics focuses on gene editing to treat genetic diseases, Regenxbio specializes in gene delivery using its AAV platform to introduce therapeutic genes into cells.

REGENXBIO (RGNX) offers the following major products and services:

• RGX-314: A gene therapy candidate in Phase III clinical trial for the treatment of wet age-related macular degeneration.
• RGX-121: A gene therapy candidate in Phase I/II clinical trial to treat mucopolysaccharidosis type II.
• RGX-111: A gene therapy candidate in Phase I/II clinical trial for treating mucopolysaccharidosis type I.
• RGX-181: A preclinical gene therapy candidate for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease.
• RGX-202: A gene therapy candidate in Phase I/II clinical trial to treat Duchenne muscular dystrophy.
• RGX-381: A preclinical gene therapy candidate to treat the ocular manifestations of CLN2 disease.
• NAV Technology Platform Licensing: Licensing its proprietary adeno-associated virus gene delivery platform to other biotechnology and pharmaceutical companies, including collaborations for novel gene therapies.

Regenxbio (RGNX) is a clinical-stage biotechnology company. As such, it does not currently sell finished pharmaceutical products directly to individuals (patients).

Based on the provided description, its major customers are other companies that license its proprietary technology platform or collaborate on the development of gene therapies.

The primary category of customers for Regenxbio is:

• Other biotechnology and pharmaceutical companies: These companies license Regenxbio's NAV Technology Platform for their own product development.

One specific customer company mentioned in the description is:

• Neurimmune AG (private company)

• Catalent, Inc. (CTLT)

Curran M. Simpson, President and Chief Executive Officer, Board Member

Curran M. Simpson was appointed President and Chief Executive Officer of REGENXBIO, effective July 1, 2024. He previously served as the company's Chief Operating Officer since January 2023, overseeing Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015, initially as Chief Technology and Operations Officer. Before REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). He also served as interim CEO at Human Genome Sciences (HGS), where he led its integration into GSK, and held senior operational roles at HGS. Earlier in his career, Mr. Simpson was Director of Manufacturing Sciences at Biogen and held development and engineering roles at Genentech, working on products such as Herceptin® and Avastin®.

Mitchell Chan, Executive Vice President and Chief Financial Officer, Treasurer and Principal Accounting Officer

Mitchell Chan was appointed Executive Vice President and Chief Financial Officer of REGENXBIO, effective September 17, 2024, bringing nearly two decades of biopharmaceutical financial leadership experience. Most recently, he served as Operating Partner at Catalio Capital Management, LP, a venture capital firm, where he acted as CFO for several portfolio companies and provided investment advice. From 2018 to 2021, Mr. Chan was the Chief Financial Officer of Viela Bio, Inc., overseeing a successful IPO and the company's $3.1 billion acquisition by Horizon Therapeutics plc. Prior to Viela, he held various financial and investor relations leadership roles at AstraZeneca and Genentech-Roche. He has served on the Board of Directors of Avalo Therapeutics since 2021.

Kenneth T. Mills, Chairman of the Board

Kenneth T. Mills co-founded REGENXBIO Inc. in 2009 and served as its President and Chief Executive Officer from inception until July 2024, when he transitioned to Chairman of the Board. He led REGENXBIO's initial public offering on Nasdaq in 2015. Prior to co-founding REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company, where he was part of the original management team and helped establish operations and financing strategies. From 1997 to 2003, he was Director of Business Development at IGEN International, a medical diagnostics firm, until its acquisition by Roche Diagnostics. Between 2007 and 2015, Mr. Mills was a partner at FoxKiser, a life sciences consulting firm. He currently also serves as President, Chief Executive Officer, and director of Tagworks Pharmaceuticals BV.

Patrick J. Christmas II, J.D., Executive Vice President, Chief Strategy Officer and Chief Legal Officer

Patrick J. Christmas II has over 15 years of leadership experience in life sciences and public markets. Before joining REGENXBIO, he was Vice President, General Counsel and Secretary at Lumara Health (formerly KV Pharmaceutical Company) through its acquisition by AMAG Pharmaceuticals and Perrigo. Prior to Lumara Health, Mr. Christmas was General Counsel and Secretary at the Wellstat Group of Companies and General Counsel at BioVeris Corporation until its acquisition by Roche.

Ram Palanki, Pharm.D., Executive Vice President & Chief Commercial Officer

Ram Palanki has nearly 20 years of experience in the development and commercialization of biopharmaceuticals and medical devices. Before joining REGENXBIO, Dr. Palanki was Senior Vice President of Commercial for the Americas at Santen Inc. Previously, he served as an executive team member leading the strategy and operations for the pre-launch and global commercialization of a first-in-class biologic at ThromboGenics. He has held roles of increasing responsibility at several companies, including the launch of LUCENTIS® at Genentech. Dr. Palanki is also the founder and a Director of Revopsis Therapeutics, Inc. He also served as an Independent Director at Hyperion DeFi, Inc. from 2022 to 2025.

1. Clinical Trial Failures and Regulatory Approval Risk: As a clinical-stage biotechnology company, Regenxbio's success is heavily dependent on the successful outcome of its clinical trials and the subsequent ability to obtain regulatory approval for its gene therapy product candidates. The lead product candidate, RGX-314, is in Phase III, while several others are in earlier Phase I/II or preclinical stages. Failure of any of these candidates in clinical trials due to lack of efficacy, safety concerns, or inability to secure regulatory approval would significantly impact the company's prospects and financial performance.
2. Reliance on NAV Technology Platform: Regenxbio's entire pipeline and licensing strategy are based on its proprietary NAV Technology Platform, an adeno-associated virus gene delivery platform. Any unforeseen issues, limitations, or long-term safety concerns specific to the NAV Technology Platform itself could adversely affect all its product candidates and the viability of its business model.
3. Intellectual Property Protection: Regenxbio's business model relies on its proprietary NAV Technology Platform and product candidates. The company's ability to protect its intellectual property rights, including patents and trade secrets, is crucial. Challenges to or invalidation of its patents, or the inability to obtain new patent protection, could diminish its competitive advantage and impact its licensing revenue.

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on gene therapy. The addressable markets for its main product candidates are as follows:

RGX-314 for Wet Age-Related Macular Degeneration (Wet AMD)

• The global wet age-related macular degeneration (AMD) market was valued at USD 10.6 billion in 2025 and is projected to reach USD 16.7 billion by 2032.
• Another estimate places the global market at USD 10.82 billion in 2023, expected to grow to USD 17.99 billion by 2030.
• Across the top 7 markets (U.S., EU4, U.K., and Japan), the wet AMD market reached approximately USD 9,528.8 million in 2024 and is anticipated to grow to USD 18,317.5 million by 2035.
• In the United States, the market size for Wet AMD was approximately USD 2,599 million in 2023, with projections for continued growth at a Compound Annual Growth Rate (CAGR) of 6.6% by 2034.

RGX-121 for Mucopolysaccharidosis Type II (MPS II / Hunter Syndrome)

• Hunter Syndrome is an ultra-rare genetic disorder, affecting roughly 1 in 100,000 to 170,000 births.
• There are approximately 800 to 900 target patients in the U.S. and Europe for RGX-121.
• The global mucopolysaccharidosis (MPS) type II segment is projected to generate USD 236.9 million in revenue by 2025.
• The U.S. accounted for the largest Hunter Syndrome market size among the 7MM (U.S., EU4, U.K., and Japan) countries in 2025.

RGX-111 for Mucopolysaccharidosis Type I (MPS I / Hurler Syndrome)

• MPS I is a rare genetic disease, estimated to occur in 1 in 100,000 births.
• The market size for Mucopolysaccharidosis Type I in the 7MM (U.S., EU4, U.K., and Japan) was USD 145 million in 2024, with an expectation to grow to USD 297 million by 2034.
• In the U.S., the MPS I market was approximately USD 70 million in 2024, representing 48% of the total 7MM market.
• Globally, the mucopolysaccharidosis type I market was valued at US$ 625 million in 2022 and is expected to reach US$ 1,288 million by 2031.

RGX-202 for Duchenne Muscular Dystrophy (DMD)

• The global Duchenne muscular dystrophy (DMD) drug market was valued at USD 3.47 billion in 2023 and is projected to reach USD 9.91 billion by 2030.
• Another report states the global DMD treatment market is estimated to grow from US$ 4.3 billion in 2026 to US$ 13.8 billion by 2033.
• The global DMD therapeutics market size reached US$ 2.19 billion in 2024 and is expected to reach US$ 6.64 billion by 2033.
• The global Duchenne muscular dystrophy treatment market is projected to reach USD 19.18 billion by 2034.
• In the U.S., annual revenue for RGX-202 is expected to reach $163 million by 2039. North America held the largest revenue share of the global DMD drugs market in 2023, at 45.0%.

REGENXBIO Inc. (RGNX) is positioned for future revenue growth over the next two to three years, driven primarily by the advancement and potential commercialization of its lead gene therapy candidates, along with ongoing revenue from its proprietary technology platform.

Here are 3-5 expected drivers of future revenue growth for Regenxbio:

1. Commercialization of RGX-314 (sura-vec) for Wet Age-Related Macular Degeneration (AMD): REGENXBIO anticipates top-line data from its pivotal ATMOSPHERE and ASCENT trials for RGX-314 in wet AMD in the fourth quarter of 2026. If approved, RGX-314 would represent a significant new product launch, as it is positioned to be the first gene therapy for wet AMD, potentially generating substantial product revenue in late 2027 or 2028. The development of sura-vec is also part of a collaboration with AbbVie, indicating strong commercial backing.
2. Launch of RGX-202 for Duchenne Muscular Dystrophy (DMD): REGENXBIO expects to release pivotal topline data for RGX-202 in early Q2 2026 and plans to submit a Biologics License Application (BLA) under the accelerated approval pathway in mid-2026. This accelerated pathway could lead to an earlier market entry, potentially bringing product revenue from late 2026 or 2027.
3. Milestone Payments from Strategic Collaborations: A notable near-term driver is the expected $100 million milestone payment from AbbVie upon the first patient dosing in the NAVIGATE pivotal study for diabetic retinopathy, which is anticipated in the first half of 2026. Further milestone payments could materialize from other existing or new collaborations as pipeline candidates advance.
4. Continued Royalty Revenue from NAV Technology Platform Licensees: REGENXBIO currently earns royalty revenue from the sales of products, such as Zolgensma and Evrysdi, that utilize its proprietary NAV Technology Platform. The company also entered into a royalty monetization agreement for up to $250 million, securing $150 million at closing in May 2025, with an additional $50 million potentially funded by April 2027 upon achievement of Zolgensma sales milestones. This ongoing and potentially increasing royalty stream provides a stable, non-dilutive revenue component.

Share Issuance

• REGENXBIO priced an underwritten public offering of common stock and pre-funded warrants in March 2024, expecting gross proceeds of approximately $140.0 million.
• In January 2021, the company announced its intent to offer and sell $175.0 million of its common stock in an underwritten public offering.
• As of March 2026, REGENXBIO has an active $300 million shelf registration and a $150 million At-The-Market (ATM) facility that could lead to future share issuances.

Inbound Investments

• In March 2025, REGENXBIO received a non-dilutive $110.0 million upfront payment from Nippon Shinyaku as part of their partnership for the RGX-121 program.
• The company closed a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx) in May 2025, receiving $150 million at closing, with an additional $50 million expected by April 30, 2027, upon ZOLGENSMA sales milestones.
• REGENXBIO anticipates a $100 million milestone payment from AbbVie upon the first patient dosed in the Phase IIb portion of the NAAVIGATE study for diabetic retinopathy, expected in Q2 2026.

Capital Expenditures

• Capital expenditures for the last 12 months prior to March 2026 were -$2.41 million.
• Research and development expenses, which include manufacturing-related expenses, increased in 2025 to $228.3 million, up from $208.5 million in 2024, primarily for RGX-202 pivotal trials, Sura-vec, and RGX-121.
• The company continues to manufacture RGX-202 for commercial supply at its in-house Manufacturing Innovation Center.